主要目的：评估克来夫定（CLV）胶囊不同序贯疗法对比恩替卡韦（ETV）单药在核苷（酸）类似物（NAs）经治的慢性乙型肝炎病毒（HBV）感染患者中的血清学应答疗效［乙型肝炎病毒表面抗原（HBsAg）转阴率和HBsAg下降> 1 lg的受试者比例］。次要目的： ①评估CLV胶囊不同序贯疗法对比ETV单药在NAs经治的慢性HBV感染患者中的其他血清学应答疗效； ②评估CLV胶囊不同序贯疗法对比ETV单药在NAs经治的慢性HBV感染患者中的病毒学应答疗效； ③评估CLV胶囊不同序贯疗法对比ETV单药在NAs经治的慢性HBV感染患者中的组织学应答疗效； ④评估CLV胶囊不同序贯疗法对比ETV单药在NAs经治的慢性HBV感染患者中的生化学应答疗效； ⑤评估CLV胶囊不同序贯疗法对比ETV单药在NAs经治的慢性HBV感染患者中耐药性； ⑥评估CLV胶囊不同序贯疗法对比ETV单药在NAs经治的慢性HBV感染患者中的安全性。

开始日期2024-09-29

申办/合作机构

广西慧宝源医药科技有限公司

NCT04891302

/ Completed临床2期

A Double Blind, Randomized, Placebo-controlled, Multi-center, Proof of Concept Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Mild and Moderate COVID-19

The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 150 mg versus placebo once daily administration with standard of care therapy for 10 days in patients with mild and moderate COVID-19.

开始日期2021-03-19

申办/合作机构

Bukwang Pharmaceutical Co., Ltd.

NCT04347915

/ Completed临床2期

A Single Blind, Randomized, Placebo-controlled, Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients Diagnosed With Moderate COVID-19

The purpose of this clinical trial is to assess the safety and efficacy of Clevudine 120 mg versus placebo once daily administration with standard of care therapy for 14 days (maximum up to 21 days) in patients with moderate COVID-19.

开始日期2020-05-26

申办/合作机构

Bukwang Pharmaceutical Co., Ltd.

100 项与克拉夫定相关的临床结果

登录后查看更多信息

100 项与克拉夫定相关的转化医学

登录后查看更多信息

100 项与克拉夫定相关的专利（医药）

登录后查看更多信息

261

项与克拉夫定相关的文献（医药）

2025-03-24·Journal of biomolecular structure & dynamics

Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development

Article

作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.

The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.

2024-06-02·SAR AND QSAR IN ENVIRONMENTAL RESEARCH

Identification of inhibitors for neurodegenerative diseases targeting dual leucine zipper kinase through virtual screening and molecular dynamics simulations

Article

作者: Samanta, S. ; Koirala, S. ; Kar, P.

Neurodegenerative diseases lead to a gradual decline in cognitive and motor functions due to the progressive loss of neurons in the central nervous system. The role of dual leucine zipper kinase (DLK) in regulating stress responses and neuronal death pathways highlights its significance as a target against neurodegenerative diseases. The non-availability of FDA-approved drugs emphasizes a need to identify novel DLK-inhibitors. We screened NPAtlas (Natural products) and MedChemExpress (FDA-approved) libraries to identify potent ATP-competitive DLK inhibitors. ADMET analyses identified four compounds (two natural products and two FDA-approved) with favourable features. Subsequently, we performed molecular dynamics simulations to examine the binding-stability and ligand-induced conformational dynamics. Molecular mechanics Poisson Boltzmann surface area (MM-PBSA) calculations demonstrated CID139591660, dithranol, and danthron having greater affinity, while CID156581477 showed lower affinity than control sunitinib. PCA and network analysis results indicated structural and network alteration post-ligand binding. Furthermore, we identified an analogue of CID156581477 using the deep learning-based web server DeLA Drug which demonstrated a higher affinity than its parent compound and the control and identified several crucial interacting residues. Overall, our study provides significant theoretical guidance for designing potent novel DLK inhibitors and compounds that could emerge as promising drug candidates against DLK following laboratory validation.

2024-02-15·Cancer research

Fimepinostat Impairs NFκB and PI3K/AKT Signaling and Enhances Gemcitabine Efficacy in H3.3K27M-Diffuse Intrinsic Pontine Glioma

Article

作者: Yu, Hongxing ; Liu, Nian ; Zhang, Liwei ; Wang, Dan ; Yan, Kun ; Xu, Cheng ; Pan, Changcun ; Tang, Yujie ; Wang, Yi ; Hong, Yaqiang ; Guo, Shuning ; Zhou, Wei ; Xi, Qiaoran ; Wu, Wei ; Li, Haocheng

Abstract:

Diffuse intrinsic pontine glioma (DIPG) is the most aggressive pediatric brain tumor, and the oncohistone H3.3K27M mutation is associated with significantly worse clinical outcomes. Despite extensive research efforts, effective approaches for treating DIPG are lacking. Through drug screening, we identified the combination of gemcitabine and fimepinostat as a potent therapeutic intervention for H3.3K27M DIPG. H3.3K27M facilitated gemcitabine-induced apoptosis in DIPG, and gemcitabine stabilized and activated p53, including increasing chromatin accessibility for p53 at apoptosis-related loci. Gemcitabine simultaneously induced a prosurvival program in DIPG through activation of RELB-mediated NFκB signaling. Specifically, gemcitabine induced the transcription of long terminal repeat elements, activated cGAS-STING signaling, and stimulated noncanonical NFκB signaling. A drug screen in gemcitabine-treated DIPG cells revealed that fimepinostat, a dual inhibitor of HDAC and PI3K, effectively suppressed the gemcitabine-induced NFκB signaling in addition to blocking PI3K/AKT activation. Combination therapy comprising gemcitabine and fimepinostat elicited synergistic antitumor effects in vitro and in orthotopic H3.3K27M DIPG xenograft models. Collectively, p53 activation using gemcitabine and suppression of RELB-mediated NFκB activation and PI3K/AKT signaling using fimepinostat is a potential therapeutic strategy for treating H3.3K27M DIPG.

Significance::

Gemcitabine activates p53 and induces apoptosis to elicit antitumor effects in H3.3K27M DIPG, which can be enhanced by blocking NFκB and PI3K/AKT signaling with fimepinostat, providing a synergistic combination therapy for DIPG.

项与克拉夫定相关的新闻（医药）

2022-06-25

·PRNewswire

Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study

New data presented in two separate oral presentations at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022) Following 90 days of dosing, ATI-2173, in combination with tenofovir disoproxil fumarate (TDF), was generally well-tolerated with alanine aminotransferase (ALT) normalization and no ALT flares off-treatment Antios' capsid assembly modulators (CAMs) ATI-1428 and ATI-1645 show safe and potent in vitro and in vivo activity and excellent pharmacokinetic profiles DOYLESTOWN, Pa., June 25, 2022 /PRNewswire/ -- Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing transformative treatments for hepatitis B virus (HBV), today announced new data from the Phase 2a clinical trial of ATI-2173, its lead investigational proprietary drug candidate and the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in clinical development for HBV. Antios also announced new data on its 4th generation capsid assembly modulator (CAM) program evaluating ATI-1428 and ATI-1645. In the 90-day Phase 2a trial, adult patients receiving ATI-2173 in combination with tenofovir disoproxil fumarate (TDF) showed slower virologic rebound than patients receiving TDF plus placebo after stopping treatment. Additionally, in a nonclinical study, low oral doses of ATI-1428 and ATI-1645 given once-daily blocked hepatic HBV replication and reduced both serum HBV DNA and RNA to undetectable levels. These data were presented at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022). Highlights from the EASL Oral Presentation on ATI-2173 In the 90-day Phase 2a study, at 24 weeks off-treatment, 75% (n=16) of ATI-2173 plus TDF patients did not meet criteria to restart TDF treatment vs. 0% (n=4) in the TDF alone arm In the ATI-2173 plus TDF arms (n=16), alanine aminotransferase (ALT) levels normalized on-treatment and no patients receiving ATI-2173 plus TDF experienced ALT flares during the 24-week off-treatment follow-up period All patients completed 90 days of dosing with no serious adverse events or dose-limiting toxicities "These data reinforce our belief that ATI-2173 can act as a bridge on the path to an HBV cure, with the potential to provide a meaningful clinical benefit to patients," said Douglas Mayers, M.D., Chief Medical Officer, and Co-Founder of Antios. "The slower virological rebound, ALT normalization on-treatment and no off-treatment ALT flares among those on the ATI-2173 combination regimen highlight the promise of the ASPIN mechanism of action – which we believe can be complementary to all other approaches." Highlights from the EASL Oral Presentation on ATI-1428 and ATI-1645 ATI-1428 and ATI-1645 are 4th generation class II CAMs with a novel and unique ultra-potent mechanism of action designed to provide for a more targeted and beneficial antiviral response with an improved clinical safety profile due to the lack of HBV capsid accumulation in liver cells ATI-1428 and ATI-1645 have displayed strong nonclinical antiviral activity in a mouse model against the various HBV genotypes and low EC50 shift against naturally occurring variants associated with resistance to past and current CAMs In in vivo mouse experiments, ATI-1428 or ATI-1645 blocked HBV replication in the liver of immunocompetent HBV-replicating mice and prevented unnecessary T-cell mediated liver damage through non-accumulation/degradation of empty capsids in the hepatocyte Both compounds show safe and potent in vitro and in vivo activity and excellent pharmacokinetic profiles "The nonclinical data supports our view that clinical development of 4th generation CAM compounds has the potential to provide a safe and effective approach for treating HBV," said Luca Guidotti, M.D., Ph.D., Deputy Scientific Director of San Raffaele Hospital and Scientific Advisor to Antios. "By preventing the abnormal capsid accumulation that less potent CAMs induce, these ultra-potent CAMs are designed to not sensitize hepatocytes to unnecessary T cell-mediated killing. This may allow the development of safe and effective combinations with therapeutic strategies aimed at immune reactivation." These presentations can be found on the Antios website at . About ATI-2173 ATI-2173, Antios Therapeutics' lead once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate. ATI-2173 has the potential, if approved, to be a bridge to a potential cure for HBV. It is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) for HBV in clinical development, and its mechanism of action is designed to be complementary to other approaches that also seek to achieve a functional cure. About ATI-1428 and ATI-1645 ATI-1428 and ATI-1645 are 4th generation, class II capsid assembly modulators (CAMs) both with a novel and unique ultra-potent mechanism of action design that may provide for a safer and more productive interaction with the immune system. Derived from a novel chemical scaffold, these CAMs have shown strong in vitro and in vivo activity in a transgenic mouse model of HBV infection. As CAMs with an ultrapotent design preclinically inducing no abnormal accumulation of empty capsids based on an initial preclinical mouse study, ATI-1428 and ATI-1645 represent promising candidates for clinical development and have entered investigational new drug enabling development. ATI-1428 and ATI-1645 were acquired by Antios in November of 2021 from San Raffaele Hospital (OSR), Istituto Nazionale Genetica Molecolare (INGM), and IRBM/Promidis, a collaboration of Italian research institutes and a global contract research organization. About HBV Hepatitis B is a potentially life-threatening liver infection caused by HBV. HBV can cause chronic infection, which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection represents a significant unmet medical need. The World Health Organization estimates that up to 300 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately two million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options. About Antios Therapeutics, Inc. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Its lead drug candidate ATI-2173 – the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) for HBV in clinical development – has the potential, if approved, to become a potential bridge to a cure for chronic HBV. Antios is also developing a novel series of 4th generation Class II capsid assembly modulators (CAMs) to further expand Antios' portfolio of differentiated molecules that could lead to a cure for HBV. HBV is a major unmet global health problem affecting up to 300 million people worldwide, more than hepatitis C and HIV combined. For more information, please visit . SOURCE Antios Therapeutics

疫苗

2022-06-08

·PRNewswire

Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress™ 2022

DOYLESTOWN, Pa., June 8, 2022 /PRNewswire/ -- Antios Therapeutics, Inc. (Antios), a clinical-stage biopharmaceutical company developing innovative therapies to advance treatments that can provide a bridge to a cure for chronic hepatitis B virus (HBV), today announced the acceptance of oral presentations highlighting ATI-2173, Antios' lead therapeutic HBV candidate and the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) for HBV in clinical development, and ATI-1428 and ATI-1645, candidates from Antios' 4th generation capsid assembly modulators (CAM) program. These presentations will be given at the European Association for the Study of the Liver's International Liver Congress 2022 (EASL ILC 2022), taking place June 22 – 26, 2022 at the ExCeL London Exhibition Centre in London, UK. Antios will be presenting the 90-day, Phase 2a study of ATI-2173 in combination with tenofovir disoproxil fumarate (TDF). This double-blind, randomized, placebo-controlled study of 20 adult patients was designed to assess the efficacy and safety of 25 and 50 mg doses of ATI-2173 daily for 90 days in combination with TDF compared with TDF plus placebo (control) in chronic HBV-infected subjects. The primary endpoints included the percentage of patients experiencing adverse reactions and time to HBV viral load relapse. In addition to adverse reactions, as a part of the primary safety endpoint, the safety evaluations recorded off-treatment ALT flares in all treatment groups. Antios will also present preclinical data from ATI-1428 and ATI-1645, which are in investigational new drug enabling development. These candidates are class II CAMs with a novel and unique ultra-potent mechanism of action design that may provide for a more targeted and beneficial antiviral response by the immune system. To date, data in a transgenic mouse model for both compounds provide initial evidence for potent in vitro and in vivo activity, an excellent pharmacokinetic profile, and no accumulation of empty capsids in the hepatocellular cytoplasm. "We see ATI-2173 as a bridge to a cure – an important first step in the ultimate search for a cure for HBV," said Greg Mayes, Chief Executive Officer of Antios. "To date, the data have been encouraging, indicating that combining ATI-2173 with a nucleoside analogue such as TDF in a simple, once-a-day regimen has the potential to completely shut down HBV polymerase activity and viral replication. We look forward to presenting our Phase 2a data, as well as the initial data from our CAM program, at the upcoming International Liver Congress." Antios Therapeutics EASL ILC 2022 Presentation Details: Title: Sustained 12-week off treatment antiviral efficacy of ATI-2173, a novel active site polymerase inhibitor nucleotide, combined with tenofovir disoproxil fumarate in chronic hepatitis B patients, a phase 2a clinical trial (#296) Author/Presenter: Douglas Mayers, M.D. Presentation Type: Oral Presentation Date/Time: June 25, 2022, at 9:15am BST Title: Novel ultra-potent capsid assembly modulators prevent abnormal accumulation of empty capsids and associated T-cell mediated liver injury in a mouse model of hepatitis B virus infection (#291) Author/Presenter: Luca Guidotti, M.D., Ph.D. Presentation Type: Oral Presentation Date/Time: June 25, 2022, at 5:30pm BST About ATI-2173 ATI-2173, Antios Therapeutics' lead once-daily, oral drug candidate for treating HBV, is an investigational phosphoramidate prodrug of clevudine monophosphate. ATI-2173 has the potential, if approved, to be a bridge to a potential cure for HBV. It is the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) for HBV in clinical development, and its mechanism of action is designed to be complementary to other approaches that also seek to achieve a functional cure. About ATI-1428 and ATI-1645 ATI-1428 and ATI-1645 are 4th generation, class II capsid assembly modulators (CAMs), both with a novel and unique ultra-potent mechanism of action design that may provide for a more targeted, productive antiviral response by the immune system. Derived from a novel chemical scaffold, these CAMs have shown strong in vitro and in vivo activity in a transgenic mouse model of HBV infection. As CAMs with an ultrapotent design inducing no accumulation of empty capsids based on an initial preclinical mouse study, ATI-1428 and ATI-1645 represent promising candidates for clinical development and have entered investigational new drug enabling development. ATI-1428 and ATI-1645 were acquired by Antios in November of 2021 from San Raffaele Hospital (OSR), Istituto Nazionale Genetica Molecolare (INGM), and IRBM/Promidis, a collaboration of Italian research institutes and a global contract research organization. About HBV Hepatitis B is a potentially life-threatening liver infection caused by HBV. HBV can cause chronic infection, which leads to a higher risk of death from cirrhosis and liver cancer. Chronic HBV infection represents a significant unmet medical need. The World Health Organization estimates that up to 300 million people worldwide suffer from chronic HBV infection, while other estimates indicate that approximately two million people in the United States suffer from chronic HBV infection. Approximately 900,000 people die every year from complications related to chronic HBV infection despite the availability of effective vaccines and current treatment options. About Antios Therapeutics, Inc. Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Its lead drug candidate ATI-2173 – the only Active Site Polymerase Inhibitor Nucleotide (ASPIN) for HBV in clinical development – has the potential, if approved, to become a potential bridge to a cure for chronic HBV. Antios is also developing a novel series of 4th generation capsid assembly modulators (CAMs) to further expand Antios' portfolio of differentiated molecules in the HBV space. HBV is a major unmet global health problem affecting up to 300 million people worldwide, more than hepatitis C and HIV combined. For more information, please visit . SOURCE Antios Therapeutics

疫苗

2022-05-25

·BioSpace

Clinical Hold on Antios’ HBV Therapy Ends Deal with Assembly

Antios Therapeutics received a clinical hold on its Hepatitis B virus (HBV) combinatorial therapy from the U.S. Food and Drug Administration on Wednesday. Antios Therapeutics received a clinical hold on its Hepatitis B virus (HBV) combinatorial therapy from the U.S. Food and Drug Administration on Wednesday. The action has resulted in the termination of a collaboration agreement between Antios and Assembly Biosciences . Antios was in two collaborative deals for its therapeutic ATI-2173, an oral drug candidate for chronic HBV. In December 2021, Antios and Arbutus Biopharma announced that the first patient was dosed in a Phase IIa combination trial of ATI-2173 and AB-729, an RNA interference therapeutic. In October 2021, Antios and Assembly Biosciences entered into a clinical collaboration agreement to evaluate ATI-2173 and vebicorvir, an HBV core inhibitor, as a combinatorial treatment for chronic HBV infection. Now, Assembly has chosen to cut ties with Antios over the clinical hold. In a regulatory filing, Assembly stated that Antios notified the company of the clinical hold, which was established based on a safety report involving a patient who received a triple combination therapy and a nucleos(t)ide analog reverse transcriptase inhibitor. Antios CEO Greg Mayes told Fierce Biotech that the company does not believe the adverse event to be related to the therapy, but that the FDA has requested an independent cardiology review of the asset. It does not seem that the deal between Antios and Arbutus is off the table yet, though. The two companies are investigating a different combinatorial treatment than the one which was penned with Assembly. The trial is investigating ATI-2173, AB-729 and tenofovir disoproxil fumarate in patients with chronic HBV infection. However, the clinical trial is bound to face similar setbacks as ATI-2173 undergoes investigation. ATI-2173 is an investigational phosphoramidate prodrug of clevudine monophosphate. The drug works to curb HBV by inhibiting HBV polymerase, and Antios has stated previously that if the drug is approved, it could become the cornerstone of curative treatment for HBV. The mechanism of action behind ATI-2173 is designed to be complementary to other treatments seeking a curative approach to HBV, hence the collaborations. In studies of ATI-2173, a single oral dose demonstrated 82% hepatic extraction. In the Assembly and Antios collaborative trials, ATI-2173 was to be paired with vebicorvir, Assembly’s lead core inhibitor and tenofovir disoproxil fumarate. In Phase II clinical trials, vebicorvir administered with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy led to greater viral suppression of both HBV DNA and HBV pgRNA than NrtI therapy alone. Assembly is also in collaborative cahoots with Arbutus Biopharma, testing vebicorvir in combination with AB-729 for patients with chronic HBV infection. The two entered into a collaboration agreement in August 2020, and Assembly recently announced that it anticipates completing enrollment for its clinical trial with Arbutus in the first half of 2022. Assembly is also investigating core inhibitor ABI-H3733 for HBV in a stand-alone monotherapeutic trial. Chronic HBV infection remains an important target for innovative treatment. Although treatment with immune modulator drugs and antiviral drugs can slow down the risk of developing more serious liver disease, there is no complete cure for the condition which can cause cirrhosis, liver failure or liver cancer.

临床2期临床结果siRNA

100 项与克拉夫定相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03537	克拉夫定	J05AF12	DB06683

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
乙型肝炎	韩国	Bukwang Pharmaceutical Co., Ltd.	2001-06-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
持续性多克隆B淋巴细胞增多症	临床3期	韩国	Bukwang Pharmaceutical Co., Ltd.	2007-12-01
慢性肝炎	临床3期	美国	Pharmasset, Inc.	2007-08-01
慢性肝炎	临床3期	中国	Pharmasset, Inc.	2007-08-01
慢性肝炎	临床3期	阿根廷	Pharmasset, Inc.	2007-08-01
慢性肝炎	临床3期	澳大利亚	Pharmasset, Inc.	2007-08-01
慢性肝炎	临床3期	巴西	Pharmasset, Inc.	2007-08-01
慢性肝炎	临床3期	加拿大	Pharmasset, Inc.	2007-08-01
慢性肝炎	临床3期	希腊	Pharmasset, Inc.	2007-08-01
慢性肝炎	临床3期	波多黎各	Pharmasset, Inc.	2007-08-01
慢性肝炎	临床3期	西班牙	Pharmasset, Inc.	2007-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASN2014	N/A	慢性乙型肝炎 hypertension \| diabetes \| history of liver or kidney transplantation ... 更多	4,178	Lamivudine	築鏇餘廠構獵憲選鹽廠(襯襯糧窪網構顧糧蓋鑰) = 憲範鹹鬱鹽鑰鑰廠顧簾鏇窪廠簾襯憲製糧鬱醖 (鑰夢範構襯鬱構範願鏇 )	-	2014-11-11
				Clevudine	築鏇餘廠構獵憲選鹽廠(襯襯糧窪網構顧糧蓋鑰) = 糧窪憲壓壓壓製鹽糧範鏇窪廠簾襯憲製糧鬱醖 (鑰夢範構襯鬱構範願鏇 )
NCT00313274 (Pubmed \| Hepatology)	临床3期	慢性乙型肝炎	86	Clevudine 30 mg	觸鑰網鹽範糧選壓積築(衊積齋鬱齋選餘憲壓醖) = 餘憲築醖憲網憲膚膚範製鑰憲膚醖鏇鹹膚夢鹽 (鹽憲製淵糧壓鑰夢淵艱 ) 更多	-	2007-10-01
				Placebo	觸鑰網鹽範糧選壓積築(衊積齋鬱齋選餘憲壓醖) = 糧醖繭簾蓋鏇鏇構壓齋製鑰憲膚醖鏇鹹膚夢鹽 (鹽憲製淵糧壓鑰夢淵艱 ) 更多